Zacks Research Analysts Reduce Earnings Estimates for HealthEquity, Inc. (NASDAQ:HQY)

HealthEquity, Inc. (NASDAQ:HQY) – Stock analysts at Zacks Research decreased their Q1 2026 earnings per share estimates for shares of HealthEquity in a research note issued to investors on Monday, September 30th. Zacks Research analyst R. Department now expects that the company will post earnings per share of $0.68 for the quarter, down from their prior forecast of $0.69. The consensus estimate for HealthEquity’s current full-year earnings is $2.25 per share.

HealthEquity (NASDAQ:HQY) last announced its earnings results on Tuesday, September 3rd. The company reported $0.66 EPS for the quarter, beating the consensus estimate of $0.50 by $0.16. The business had revenue of $299.93 million for the quarter, compared to the consensus estimate of $284.48 million. HealthEquity had a return on equity of 9.01% and a net margin of 9.61%.

Several other equities research analysts also recently commented on HQY. Bank of America dropped their target price on HealthEquity from $105.00 to $100.00 and set a “buy” rating on the stock in a report on Wednesday, September 4th. Deutsche Bank Aktiengesellschaft raised their price objective on HealthEquity from $102.00 to $103.00 and gave the company a “buy” rating in a research note on Wednesday, September 4th. Raymond James raised their price objective on HealthEquity from $100.00 to $105.00 and gave the company an “outperform” rating in a research note on Friday, June 7th. Wells Fargo & Company raised their price objective on HealthEquity from $107.00 to $110.00 and gave the company an “overweight” rating in a research note on Thursday, June 20th. Finally, JMP Securities restated a “market outperform” rating and set a $105.00 price objective on shares of HealthEquity in a research note on Wednesday, September 4th. One analyst has rated the stock with a hold rating and twelve have given a buy rating to the company’s stock. According to data from MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus price target of $103.83.

HealthEquity Stock Performance

Shares of NASDAQ:HQY opened at $78.18 on Wednesday. The company has a market cap of $6.80 billion, a P/E ratio of 85.40, a PEG ratio of 1.25 and a beta of 0.52. The company has a debt-to-equity ratio of 0.51, a quick ratio of 4.10 and a current ratio of 4.10. HealthEquity has a one year low of $61.81 and a one year high of $88.26. The business’s 50-day simple moving average is $76.46 and its 200 day simple moving average is $79.20.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Rise Advisors LLC bought a new stake in HealthEquity during the 1st quarter valued at $28,000. International Assets Investment Management LLC bought a new stake in HealthEquity during the 2nd quarter valued at $35,000. YHB Investment Advisors Inc. bought a new stake in HealthEquity during the 1st quarter valued at $40,000. Fidelis Capital Partners LLC bought a new stake in HealthEquity during the 1st quarter valued at $42,000. Finally, Parallel Advisors LLC raised its stake in HealthEquity by 255.5% during the 4th quarter. Parallel Advisors LLC now owns 679 shares of the company’s stock valued at $45,000 after acquiring an additional 488 shares in the last quarter. Institutional investors and hedge funds own 99.55% of the company’s stock.

Insider Transactions at HealthEquity

In other news, Vice Chairman Stephen Neeleman sold 35,000 shares of HealthEquity stock in a transaction that occurred on Thursday, July 25th. The stock was sold at an average price of $79.86, for a total value of $2,795,100.00. Following the completion of the transaction, the insider now owns 89,769 shares in the company, valued at approximately $7,168,952.34. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. In related news, Director Frank Corvino sold 7,705 shares of the business’s stock in a transaction that occurred on Monday, July 8th. The stock was sold at an average price of $81.89, for a total transaction of $630,962.45. Following the completion of the transaction, the director now owns 6,070 shares in the company, valued at approximately $497,072.30. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, Vice Chairman Stephen Neeleman sold 35,000 shares of the business’s stock in a transaction that occurred on Thursday, July 25th. The shares were sold at an average price of $79.86, for a total value of $2,795,100.00. Following the transaction, the insider now owns 89,769 shares of the company’s stock, valued at approximately $7,168,952.34. The disclosure for this sale can be found here. In the last quarter, insiders sold 43,952 shares of company stock worth $3,526,147. 2.20% of the stock is currently owned by corporate insiders.

HealthEquity Company Profile

HealthEquity, Inc provides technology-enabled services platforms to consumers and employers in the United States. The company offers cloud-based platforms for individuals to make health saving and spending decisions, pay healthcare bills, receive personalized benefit information, earn wellness incentives, grow their savings, and make investment choices; and health savings accounts.